Nara Organics is voluntarily recalling all of its infant formula sold in the United States after the Food and Drug Administration and the Centers for Disease Control and Prevention flagged three cases of infant botulism in babies who had consumed the product.

Novo Nordisk (NOVO) plans to submit its oral Wegovy weight-loss pill for Chinese regulatory approval within a few months, Chief Executive Mike Doustdar said, as the Danish drugmaker seeks to close the gap with rival Eli Lilly (LLY) in the world's second-largest pharmaceutical market.

Sixth Street Partners and KKR & Co (KKR) have agreed to provide $1 billion in preferred equity financing to BridgeBio Pharma (BBIO), according to people familiar with the matter, in one of the largest biotech deals so far this year.

Ananym Capital Management has built a stake in Bio-Techne Corp (TECH) and is pressing the company's board to launch a strategic review that would include weighing a potential sale, according to a letter reviewed by Bloomberg News.

Zepzelca, the small-cell lung cancer treatment sold by Jazz Pharmaceuticals (JAZZ) and developed with Spain's PharmaMar (PHM), has failed a phase 3 trial on its primary endpoint of overall survival, threatening the drug's original accelerated approval for the second time in its history.

Alnylam Pharmaceuticals (ALNY) shares fell to a 52-week low of $282.71 in mid June, just above the yearly trough of $283.10, extending a slide that has knocked more than a quarter off the drugmaker's valuation in 2026.

The US Food and Drug Administration has expanded approval of Dexcom's (DXCM) Stelo Glucose Biosensor System to include children with diabetes, making it the first over-the-counter continuous glucose monitor cleared for pediatric use.

The US Food and Drug Administration has approved an expanded label for Sanofi's (SNY) type 1 diabetes treatment Tzield, allowing its use in children aged 8 to 17 who have recently been diagnosed with stage 3 of the disease.

Spyre Therapeutics (SYRE) said its experimental ulcerative colitis treatment significantly reduced disease severity in a mid-stage clinical trial, marking a key milestone for the biotech's inflammation pipeline.

Shares in Elicio Therapeutics (ELTX) fell roughly 72% after the biotech company's experimental pancreatic cancer vaccine failed to meaningfully extend the time patients lived without disease recurrence, missing the primary endpoint of a mid-stage clinical study.